EW · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

Edwards Lifesciences Corp · 2026-11-04 · Importance 54 · Surprise 40 · In source text

Net sales for the nine months ended September 30, 2026 increased 13.5% to $5,105.1 million from $4,498.0 million, a $607.1 million gain. TAVR sales rose 11.1% to $3,697.2 million, TMTT sales rose 47.7% to $583.2 million, and Surgical sales increased 6.3% to $824.7 million. For the third quarter, total sales increased 10.5% to $1,715.5 million, with TMTT growing 44.3% to $209.5 million. Nine-month sales increased across every reported region, led by Europe at 17.0% and Rest of World at 19.3%.

Key facts

• Edwards Lifesciences reported net sales of $5.1 billion for the first nine months of 2026, an increase of $607.1 million from the first nine months of 2025, driven primarily by TAVR and TMTT products. source
• TAVR sales increased in the three and nine months ended September 30, 2026, driven by higher Edwards SAPIEN platform sales, primarily the SAPIEN 3 Ultra RESILIA valve in the United States, Europe, and Japan. source
• TMTT sales increased in the three and nine months ended September 30, 2026, primarily from higher PASCAL, EVOQUE, and SAPIEN M3 sales in the United States and Europe. source
• Surgical sales increased in the three and nine months ended September 30, 2026, primarily from higher INSPIRIS RESILIA, KONECT RESILIA, and MITRIS RESILIA sales in the United States and Europe. source

Impact estimates